[et_pb_section fb_built=”1″ admin_label=”slider_englisch” _builder_version=”4.16″ custom_padding=”17px||36px||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ width=”90%” max_width=”1600px” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_image src=”https:\/\/embolog.serumwerk.de\/wp-content\/uploads\/2024\/11\/Header_2024_E.jpg” title_text=”Header_2024_E” _builder_version=”4.21.0″ z_index=”-112″ hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_class=”diagonal-shadow” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.21.0″ custom_padding=”||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text content_tablet=”<\/p>\n
” content_phone=”<\/p>\n
” content_last_edited=”on|desktop” _builder_version=”4.21.0″ header_font=”|700|||||||” header_text_align=”center” header_text_color=”#067ec7″ header_font_size_tablet=”” header_font_size_phone=”26px” header_font_size_last_edited=”on|phone” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_divider show_divider=”off” _builder_version=”4.21.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][et_pb_divider _builder_version=”4.16″ custom_margin=”||-10px|||” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.21.0″ text_font=”|300|||||||” text_text_color=”#067ec7″ text_font_size=”13px” text_line_height=”1.6em” header_font=”Open Sans|700|||||||” header_text_align=”center” header_text_color=”#067ec7″ text_orientation=”center” custom_margin=”-10px||10px||false|false” custom_padding=”0px||||false|false” global_colors_info=”{}”]<\/p>\n
Studies performed with (A) EmboCept\u00ae<\/sup>* and (B) EmboCept\u00ae<\/sup>*S latter being identical to current EmboLog\u00ae<\/sup> S<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ width=”90%” max_width=”1600px” custom_padding=”6px|||||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_font=”|300|||||||” global_colors_info=”{}”]<\/p>\n [1]<\/b> Vogl T, Schwarz W, Eichler K, Hochmuth K, Hammerstingl R, Jacob U et al.<\/span> Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. Journal of Cancer Research and Clinical Oncology. 2006;132(11):745-755.(A) [\/et_pb_text][et_pb_text _builder_version=”4.21.0″ text_font=”|300|||||||” global_colors_info=”{}”]*trademark of Magle PharmaCept GmbH[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" EmboLog\u00ae S – referencesStudies performed with (A) EmboCept\u00ae* and (B) EmboCept\u00ae*S latter being identical to current EmboLog\u00ae S[1] Vogl T, Schwarz W, Eichler K, Hochmuth K, Hammerstingl R, Jacob U et al. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose […]<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"[et_pb_section fb_built=\"1\" _builder_version=\"4.4.8\" custom_padding=\"17px||36px|||\" global_module=\"126\" saved_tabs=\"all\"][et_pb_row _builder_version=\"4.4.8\" width=\"90%\" max_width=\"1600px\"][et_pb_column type=\"4_4\" _builder_version=\"4.4.8\"][et_pb_image src=\"https:\/\/embolog.serumwerk.de\/wp-content\/uploads\/2020\/06\/Header-2-scaled.jpg\" title_text=\"Header 2\" _builder_version=\"4.4.8\" z_index=\"-112\"][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\"1\" module_class=\"diagonal-shadow\" _builder_version=\"4.4.8\"][et_pb_row _builder_version=\"4.4.8\" custom_padding=\"3px|||||\"][et_pb_column type=\"4_4\" _builder_version=\"4.4.8\"][et_pb_text _builder_version=\"4.4.8\" header_font=\"Open Sans|700|||||||\" header_text_align=\"center\" header_text_color=\"#067ec7\"] [1]<\/b> Vogl T, Schwarz W, Eichler K, Hochmuth K, Hammerstingl R, Jacob U et al.<\/span> Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. Journal of Cancer Research and Clinical Oncology. 2006;132(11):745-755.
[2]<\/b> Nabil M, Gruber T, Yakoub D, Ackermann H, Zangos S, Vogl TJ. Repetitive transarterial chemoembolization (TACE) of liver metastases\u00a0from renal cell carcinoma: local control and survival results. Eur Radiol. 2008 Jul;18(7):1456\u201363.(A)
[3]<\/b> Vogl T, Gruber T, Balzer J, Eichler K, Hammerstingl R, Zangos S. Repeated Transarterial Chemoembolization in the Treatment of Liver Metastases of Colorectal Cancer: Prospective Study. Radiology. 2009-1;250(1):281-289.(A)
[4]<\/b> Vogl T, Gruber T, Naguib N, Hammerstingl R, Nour-Eldin N. Liver Metastases of Neuroendocrine Tumors: Treatment With Hepatic Transarterial Chemotherapy Using Two Therapeutic Protocols. American Journal of Roentgenology. 2009-2;193(4):941-947.(A)
[5]<\/b> Vogl T, Naguib N, Nour-Eldin N, Eichler K, Zangos S, Gruber-Rouh T. Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. European Radiology. 2009;20(1):173-180.(A)
[6]<\/b> Vogl T, Naguib N, Nour-Eldin N, Mack M, Zangos S, Abskharon J et al.<\/span> Repeated Chemoembolization Followed by Laser-Induced Thermotherapy for Liver Metastasis of Breast Cancer. American Journal of Roentgenology. 2011;196(1):W66-W72.(A)
[7]<\/b> Azizi A, Naguib N, Mbalisike E, Farshid P, Emami A, Vogl T. Liver Metastases of Pancreatic Cancer. Pancreas. 2011;40(8):1271-1275.(A)
[8]<\/b> Vogl T, Naguib N, Lehnert T, Nour-Eldin N, Eichler K, Zangos S et al.<\/span> Initial experience with repetitive transarterial chemoembolization (TACE) as a third line treatment of ovarian cancer metastasis to the liver: Indications, outcomes and role in patient’s management. Gynecologic Oncology. 2012;124(2):225-229.(A)
[9]<\/b> Vogl TJ, Jost A, Nour-Eldin NA, Mack MG, Zangos S, Naguib NNN. Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma. Br J Cancer. 2012 Mar 27;106(7):1274\u20139.(A)
[10]<\/b> Wiggermann P, Heibl M, Niessen C, M\u00fcller-Wille R, G\u00f6ssmann H, Uller W, et al.<\/span> Degradable starch microspheres transarterial chemoembolisation (DSM-TACE) of HCC: Dynamic Contrast-Enhanced Ultrasonography (DCE-US) based evaluation of therapeutic efficacy using a novel perfusion software. Clin Hemorheol Microcirc. 2012;52(2\u20134):123\u20139.(B)
[11]<\/b> Farshid P, Darvishi A, Naguib N, Bazrafshan B, Paul J, Mbalisike E et al.<\/span> Repetitive chemoembolization of hypovascular liver metastases from the most common primary sites. Future Oncology. 2013;9(3):419-426.(A)
[12]<\/b> Vogl T, Gruber-Rouh T, Eichler K, Nour-Eldin N, Trojan J, Zangos S et al.<\/span> Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: Local control and survival results. European Journal of Radiology. 2013;82(2):258-263.(A)
[13]<\/b> Heibl M, Jung EM, Beyer L, Wohlgemuth WA, Stroszczynski C, Wiggermann P. Aggregated time intensity curves after transarterial chemoembolization with degradable starch microspheres: a feasibility study. Clin Hemorheol Microcirc. 2013 Jan 1;55(4):417\u201321.(B)
[14]<\/b> Eichler K, Jakobi S, Gruber-Rouh T, Hammerstingl R, Vogl TJ, Zangos S. Transarterial chemoembolisation (TACE) with gemcitabine:\u00a0phase II study in patients with liver metastases of breast cancer. Eur J Radiol. 2013 Dec;82(12):e816-822.(A)
[15]<\/b> Wiggermann P, Wohlgemuth WA, Heibl M, Vasilj A, Loss M, Schreyer AG, et al.<\/span> Dynamic evaluation and quantification of\u00a0microvascularization during degradable starch microspheres transarterial Chemoembolisation (DSM-TACE) of HCC lesions using\u00a0contrast enhanced ultrasound (CEUS): a feasibility study. Clin Hemorheol Microcirc. 2013;53(4):337\u201348.(B)
[16] <\/b>Gruber-Rouh T, Naguib N, Eichler K, Ackermann H, Zangos S, Trojan J et al.<\/span> Transarterial chemoembolization of unresectable\u00a0systemic chemotherapy-refractory liver metastases from colorectal cancer: Long-term results over a 10-year period. International\u00a0Journal of Cancer. 2013;134(5):1225-1231.(A)
[17]<\/b> Vogl T, Kreutztr\u00e4ger M, Gruber-Rouh T, Eichler K, Nour-Eldin N, Zangos S et al.<\/span> Neoadjuvant TACE before laser induced\u00a0thermotherapy (LITT) in the treatment of non-colorectal non-breast cancer liver metastases: Feasibility and survival rates.\u00a0European Journal of Radiology. 2014;83(10):1804-1810.(A)
[18]<\/b> Niessen C, Unterpaintner E, Goessmann H, Schlitt HJ, Mueller-Schilling M, Wohlgemuth WA, et al.<\/span> Degradable starch microspheres\u00a0versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol JVIR. 2014\u00a0Feb;25(2):240\u20137.(A)
[19]<\/b> Orlacchio A, Chegai F, Merolla S, Francioso S, Giudice CD, Angelico M, et al.<\/span> Downstaging disease in patients with hepatocellular\u00a0carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization. World J Hepatol. 2015 Jun 28;7(12):1694\u2013700.(B)
[20]<\/b> Schicho A, Hellerbrand C, Kr\u00fcger K, Beyer L, Wohlgemuth W, Niessen C et al.<\/span> Impact of Different Embolic Agents for Transarterial\u00a0Chemoembolization (TACE) Procedures on Systemic Vascular Endothelial Growth Factor (VEGF) Levels. Journal of Clinical and\u00a0Translational Hepatology. 2016;4(4):288-292.(B)
[21]<\/b> Schicho A, Pereira P, Haimerl M, Niessen C, Michalik K, Beyer L et al.<\/span> Transarterial chemoembolization (TACE) with degradable\u00a0starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy. Oncotarget.\u00a02017;8(42):72613-72620.(A)
[22]<\/b> Vogl T, Mohamed S, Albrecht M, Gruber-Roh T, Lin H, Nour Eldin N et al.<\/span> Transarterial chemoembolization in pancreatic\u00a0adenocarcinoma with liver metastases: MR-based tumor response evaluation, apparent diffusion coefficient (ADC) patterns, and\u00a0survival rates. Pancreatology. 2018;18(1):94-99.(A)
[23]<\/b> Vogl T, Lahrsow M, Albrecht M, Hammerstingl R, Thompson Z, Gruber-Rouh T. Survival of patients with non-resectable,\u00a0chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial\u00a0chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation. European Journal of\u00a0Radiology. 2018;102:138-145.(A)
[24]<\/b> Schicho A, Pereira P, Michalik K, Beyer L, Stroszczynski C, Wiggermann P. Safety and efficacy of transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in the treatment of secondary liver malignancies. OncoTargets and Therapy. 2018;Volume 11:345-350.(B)
[25] <\/b>Gruber-Rouh T, Kamal A, Eichler K, Naguib N, Beeres M, Langenbach M et al.<\/span> Transarterial Chemoembolization (TACE) Using Mitomycin with or without Irinotecan for Hepatocellular Carcinoma in European Patients. Oncology Research and Treatment. 2018;41(7-8):438-442.(B)
[26]<\/b> Gruber-Rouh T, Schmitt C, Naguib N, Nour-Eldin N, Eichler K, Beeres M et al.<\/span> Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study. BMCCancer. 2018;18(1).(B)
[27]<\/b> Iezzi R, Pompili M, Rinninella E, Annicchiarico E, Garcovich M, Cerrito L et al.<\/span> TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. European Radiology. 2018;29(3):1285-1292.(A)
[28]<\/b> Larsen F, Jensen B, N\u00f8rgaard H, Hermann H, Larsen P, Markussen A et al.<\/span> Intrahepatic Oxaliplatin and Systemic 5-FU +\/\u2013 Cetuximab in Chemo-Na\u00efve Patients with Liver Metastases from Colorectal Cancer. Oncology. 2019;96(6):299-308.(B)
[29]<\/b> Lindgaard S, Brinch C, Jensen B, N\u00f8rgaard H, Hermann K, Theile S et al.<\/span> Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer. The Breast. 2019;43:113-119.(B)
[30]<\/b> Lucatelli P, De Rubeis G, Basilico F, Ginanni Corradini L, Corona M, Bezzi M et al.<\/span> Sequential dual-phase cone-beam CT is able to intra-procedurally predict the one-month treatment outcome of multi-focal HCC, in course of degradable starch microsphere TACE. La radiologia medica. 2019;124(12):1212-1219.(B)
[31]<\/b> Orlacchio A, Chegai F, Roma S, Merolla S, Bosa A, Francioso S. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study. La radiologia medica. 2019;125(1):98-106.(A)
[32] <\/b>Goerg F, Zimmermann M, Bruners P, Neumann U, Luedde T, Kuhl C. Chemoembolization with Degradable Starch Microspheres for Treatment of Patients with Primary or Recurrent Unresectable, Locally Advanced Intrahepatic Cholangiocarcinoma: A Pilot Study. CardioVascular and Interventional Radiology. 2019;42(12):1709-1717.(B)
[33]<\/b> Haubold J, Reinboldt M, Wetter A, Li Y, Ludwig J, Lange C et al.<\/span> DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies. R\u00f6Fo – Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der bildgebenden Verfahren. 2020.(B)
[34]<\/b> Gross A, Albrecht T. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy. CardioVascular and Interventional Radiology. 2019;43(3):402-410.(B)
[35]<\/b> Ziemann C, Roller J, Malter M, Keller K, Kollmar O, Glanemann M et al.<\/span> Intra-arterial EmboCept S\u00ae<\/sup> and DC Bead\u00ae<\/sup> effectively inhibit tumor growth of colorectal rat liver metastases. BMC Cancer. 2019;19(1).
[36]<\/b> Paprottka KJ, Waggershauser T, R\u00fcbenthaler J, Paprottka FJ, Clevert DA, Reiser MF, et al.<\/span> In vitro study of physical properties of\u00a0various embolization particles regarding morphology before, during and after catheter passage. Clin Hemorheol Microcirc. 2016;64(4):887\u201398.(A)<\/p>\nEmboLog\u00ae<\/sup> S - Referenzen<\/h1>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\"4.4.8\" width=\"90%\" max_width=\"1600px\" custom_padding=\"6px|||||\"][et_pb_column type=\"4_4\" _builder_version=\"4.4.8\"][et_pb_text _builder_version=\"4.4.8\" text_font=\"|300|||||||\" hover_enabled=\"0\"]
[2]<\/b> Nabil M, Gruber T, Yakoub D, Ackermann H, Zangos S, Vogl TJ. Repetitive transarterial chemoembolization (TACE) of liver metastases\u00a0from renal cell carcinoma: local control and survival results. Eur Radiol. 2008 Jul;18(7):1456\u201363.
[3]<\/b> Vogl T, Gruber T, Balzer J, Eichler K, Hammerstingl R, Zangos S. Repeated Transarterial Chemoembolization in the Treatment of Liver Metastases of Colorectal Cancer: Prospective Study. Radiology. 2009-1;250(1):281-289.
[4]<\/b> Vogl T, Gruber T, Naguib N, Hammerstingl R, Nour-Eldin N. Liver Metastases of Neuroendocrine Tumors: Treatment With Hepatic Transarterial Chemotherapy Using Two Therapeutic Protocols. American Journal of Roentgenology. 2009-2;193(4):941-947.
[5]<\/b> Vogl T, Naguib N, Nour-Eldin N, Eichler K, Zangos S, Gruber-Rouh T. Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. European Radiology. 2009;20(1):173-180.
[6]<\/b> Vogl T, Naguib N, Nour-Eldin N, Mack M, Zangos S, Abskharon J et al.<\/span> Repeated Chemoembolization Followed by Laser-Induced Thermotherapy for Liver Metastasis of Breast Cancer. American Journal of Roentgenology. 2011;196(1):W66-W72.
[7]<\/b> Azizi A, Naguib N, Mbalisike E, Farshid P, Emami A, Vogl T. Liver Metastases of Pancreatic Cancer. Pancreas. 2011;40(8):1271-1275.
[8]<\/b> Vogl T, Naguib N, Lehnert T, Nour-Eldin N, Eichler K, Zangos S et al.<\/span> Initial experience with repetitive transarterial chemoembolization (TACE) as a third line treatment of ovarian cancer metastasis to the liver: Indications, outcomes and role in patient's management. Gynecologic Oncology. 2012;124(2):225-229.
[9]<\/b> Vogl TJ, Jost A, Nour-Eldin NA, Mack MG, Zangos S, Naguib NNN. Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma. Br J Cancer. 2012 Mar 27;106(7):1274\u20139.
[10]<\/b> Wiggermann P, Heibl M, Niessen C, M\u00fcller-Wille R, G\u00f6ssmann H, Uller W, et al.<\/span> Degradable starch microspheres transarterial chemoembolisation (DSM-TACE) of HCC: Dynamic Contrast-Enhanced Ultrasonography (DCE-US) based evaluation of therapeutic efficacy using a novel perfusion software. Clin Hemorheol Microcirc. 2012;52(2\u20134):123\u20139.
[11]<\/b> Farshid P, Darvishi A, Naguib N, Bazrafshan B, Paul J, Mbalisike E et al.<\/span> Repetitive chemoembolization of hypovascular liver metastases from the most common primary sites. Future Oncology. 2013;9(3):419-426.
[12]<\/b> Vogl T, Gruber-Rouh T, Eichler K, Nour-Eldin N, Trojan J, Zangos S et al.<\/span> Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: Local control and survival results. European Journal of Radiology. 2013;82(2):258-263.
[13]<\/b> Heibl M, Jung EM, Beyer L, Wohlgemuth WA, Stroszczynski C, Wiggermann P. Aggregated time intensity curves after transarterial chemoembolization with degradable starch microspheres: a feasibility study. Clin Hemorheol Microcirc. 2013 Jan 1;55(4):417\u201321.
[14]<\/b> Eichler K, Jakobi S, Gruber-Rouh T, Hammerstingl R, Vogl TJ, Zangos S. Transarterial chemoembolisation (TACE) with gemcitabine:\u00a0phase II study in patients with liver metastases of breast cancer. Eur J Radiol. 2013 Dec;82(12):e816-822.
[15]<\/b> Wiggermann P, Wohlgemuth WA, Heibl M, Vasilj A, Loss M, Schreyer AG, et al.<\/span> Dynamic evaluation and quantification of\u00a0microvascularization during degradable starch microspheres transarterial Chemoembolisation (DSM-TACE) of HCC lesions using\u00a0contrast enhanced ultrasound (CEUS): a feasibility study. Clin Hemorheol Microcirc. 2013;53(4):337\u201348.
[16] <\/b>Gruber-Rouh T, Naguib N, Eichler K, Ackermann H, Zangos S, Trojan J et al.<\/span> Transarterial chemoembolization of unresectable\u00a0systemic chemotherapy-refractory liver metastases from colorectal cancer: Long-term results over a 10-year period. International\u00a0Journal of Cancer. 2013;134(5):1225-1231.
[17]<\/b> Vogl T, Kreutztr\u00e4ger M, Gruber-Rouh T, Eichler K, Nour-Eldin N, Zangos S et al.<\/span> Neoadjuvant TACE before laser induced\u00a0thermotherapy (LITT) in the treatment of non-colorectal non-breast cancer liver metastases: Feasibility and survival rates.\u00a0European Journal of Radiology. 2014;83(10):1804-1810.
[18]<\/b> Niessen C, Unterpaintner E, Goessmann H, Schlitt HJ, Mueller-Schilling M, Wohlgemuth WA, et al.<\/span> Degradable starch microspheres\u00a0versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol JVIR. 2014\u00a0Feb;25(2):240\u20137.
[19]<\/b> Orlacchio A, Chegai F, Merolla S, Francioso S, Giudice CD, Angelico M, et al.<\/span> Downstaging disease in patients with hepatocellular\u00a0carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization. World J Hepatol. 2015 Jun 28;7(12):1694\u2013700.
[20]<\/b> Schicho A, Hellerbrand C, Kr\u00fcger K, Beyer L, Wohlgemuth W, Niessen C et al.<\/span> Impact of Different Embolic Agents for Transarterial\u00a0Chemoembolization (TACE) Procedures on Systemic Vascular Endothelial Growth Factor (VEGF) Levels. Journal of Clinical and\u00a0Translational Hepatology. 2016;4(4):288-292.
[21]<\/b> Schicho A, Pereira P, Haimerl M, Niessen C, Michalik K, Beyer L et al.<\/span> Transarterial chemoembolization (TACE) with degradable\u00a0starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy. Oncotarget.\u00a02017;8(42):72613-72620.
[22]<\/b> Vogl T, Mohamed S, Albrecht M, Gruber-Roh T, Lin H, Nour Eldin N et al.<\/span> Transarterial chemoembolization in pancreatic\u00a0adenocarcinoma with liver metastases: MR-based tumor response evaluation, apparent diffusion coefficient (ADC) patterns, and\u00a0survival rates. Pancreatology. 2018;18(1):94-99.
[23]<\/b> Vogl T, Lahrsow M, Albrecht M, Hammerstingl R, Thompson Z, Gruber-Rouh T. Survival of patients with non-resectable,\u00a0chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial\u00a0chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation. European Journal of\u00a0Radiology. 2018;102:138-145.
[24]<\/b> Schicho A, Pereira P, Michalik K, Beyer L, Stroszczynski C, Wiggermann P. Safety and efficacy of transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in the treatment of secondary liver malignancies. OncoTargets and Therapy. 2018;Volume 11:345-350.
[25] <\/b>Gruber-Rouh T, Kamal A, Eichler K, Naguib N, Beeres M, Langenbach M et al.<\/span> Transarterial Chemoembolization (TACE) Using Mitomycin with or without Irinotecan for Hepatocellular Carcinoma in European Patients. Oncology Research and Treatment. 2018;41(7-8):438-442.
[26]<\/b> Gruber-Rouh T, Schmitt C, Naguib N, Nour-Eldin N, Eichler K, Beeres M et al.<\/span> Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study. BMCCancer. 2018;18(1).
[27]<\/b> Iezzi R, Pompili M, Rinninella E, Annicchiarico E, Garcovich M, Cerrito L et al.<\/span> TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. European Radiology. 2018;29(3):1285-1292.
[28]<\/b> Larsen F, Jensen B, N\u00f8rgaard H, Hermann H, Larsen P, Markussen A et al.<\/span> Intrahepatic Oxaliplatin and Systemic 5-FU +\/\u2013 Cetuximab in Chemo-Na\u00efve Patients with Liver Metastases from Colorectal Cancer. Oncology. 2019;96(6):299-308.
[29]<\/b> Lindgaard S, Brinch C, Jensen B, N\u00f8rgaard H, Hermann K, Theile S et al.<\/span> Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer. The Breast. 2019;43:113-119.
[30]<\/b> Lucatelli P, De Rubeis G, Basilico F, Ginanni Corradini L, Corona M, Bezzi M et al.<\/span> Sequential dual-phase cone-beam CT is able to intra-procedurally predict the one-month treatment outcome of multi-focal HCC, in course of degradable starch microsphere TACE. La radiologia medica. 2019;124(12):1212-1219.
[31]<\/b> Orlacchio A, Chegai F, Roma S, Merolla S, Bosa A, Francioso S. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study. La radiologia medica. 2019;125(1):98-106.
[32] <\/b>Goerg F, Zimmermann M, Bruners P, Neumann U, Luedde T, Kuhl C. Chemoembolization with Degradable Starch Microspheres for Treatment of Patients with Primary or Recurrent Unresectable, Locally Advanced Intrahepatic Cholangiocarcinoma: A Pilot Study. CardioVascular and Interventional Radiology. 2019;42(12):1709-1717.
[33]<\/b> Haubold J, Reinboldt M, Wetter A, Li Y, Ludwig J, Lange C et al.<\/span> DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies. R\u00f6Fo - Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der bildgebenden Verfahren. 2020.
[34]<\/b> Gross A, Albrecht T. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy. CardioVascular and Interventional Radiology. 2019;43(3):402-410.
[35]<\/b> Ziemann C, Roller J, Malter M, Keller K, Kollmar O, Glanemann M et al.<\/span> Intra-arterial EmboCept S\u00ae<\/sup> and DC Bead\u00ae<\/sup> effectively inhibit tumor growth of colorectal rat liver metastases. BMC Cancer. 2019;19(1).
[36]<\/b> Paprottka KJ, Waggershauser T, R\u00fcbenthaler J, Paprottka FJ, Clevert DA, Reiser MF, et al.<\/span> In vitro study of physical properties of\u00a0various embolization particles regarding morphology before, during and after catheter passage. Clin Hemorheol Microcirc. 2016;64(4):887\u201398.<\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]","_et_gb_content_width":""},"_links":{"self":[{"href":"https:\/\/embolog.serumwerk.de\/en\/wp-json\/wp\/v2\/pages\/547"}],"collection":[{"href":"https:\/\/embolog.serumwerk.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/embolog.serumwerk.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/embolog.serumwerk.de\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/embolog.serumwerk.de\/en\/wp-json\/wp\/v2\/comments?post=547"}],"version-history":[{"count":19,"href":"https:\/\/embolog.serumwerk.de\/en\/wp-json\/wp\/v2\/pages\/547\/revisions"}],"predecessor-version":[{"id":1478,"href":"https:\/\/embolog.serumwerk.de\/en\/wp-json\/wp\/v2\/pages\/547\/revisions\/1478"}],"wp:attachment":[{"href":"https:\/\/embolog.serumwerk.de\/en\/wp-json\/wp\/v2\/media?parent=547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}